GALECTO INC (GLTO)
US36322Q1076 - Common Stock
Galecto Reports Third Quarter 2024 Financial Results
- Completed strategic review to focus on oncology and severe liver diseases - Announced acquisition of global rights to BRM-1420, a dual ENL-YEATS and...
Galecto Strengthens Board of Directors with Appointment of Dr. Amy Wechsler
BOSTON, Oct. 15, 2024 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company focused on the development of novel...
Galecto Completes Strategic Review to Focus on Oncology and Liver Disease and Acquires Acute Myeloid Leukemia Preclinical Asset from Bridge Medicines
Galecto will focus on cancer and liver disease, leveraging existing clinical stage asset GB1211Bolsters pipeline by obtaining global rights to BRM-1420, a...
Galecto Announces Reverse Stock Split
BOSTON, Aug. 28, 2024 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company focused on the development of novel...
GLTO Stock Earnings: Galecto Beats EPS for Q2 2024
GLTO stock results show that Galecto beat analyst estimates for earnings per share the second quarter of 2024.
GLTO Stock Earnings: Galecto Beats EPS for Q2 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Galecto (NASDAQ:GLTO) just reported results for the second quarter of 2024.Gale...
GLTO Stock Earnings: Galecto Beats EPS for Q1 2024
GLTO stock results show that Galecto beat analyst estimates for earnings per share the first quarter of 2024.
GLTO Stock Earnings: Galecto Beats EPS for Q1 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Galecto (NASDAQ:GLTO) just reported results for the first quarter of 2024.Galec...
Galecto Announces First Patient Dosed in an Investigator-Initiated Phase 2 Trial of GB1211 in Combination with Pembrolizumab
An NCI-supported Phase 2 investigator-initiated trial at the Providence Cancer Institute in Portland, Oregon, has enrolled its first patient in a study...
GLTO Stock Earnings: Galecto Beats EPS for Q4 2023
GLTO stock results show that Galecto beat analyst estimates for earnings per share the fourth quarter of 2023.
GLTO Stock Earnings: Galecto Beats EPS for Q4 2023
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Galecto (NASDAQ:GLTO) just reported results for the fourth quarter of 2023.Gale...
Galecto stock rallies 25% on positive data for myelofibrosis drug (GLTO)
Galecto (GLTO) stock rallied 25% in post-market trading Thursday on positive Phase 2 data for the company's myelofibrosis drug. Read more here.
Topline Results from MYLOX-1 Trial Demonstrate Reduction in Fibrosis of the Bone Marrow in Patients with Myelofibrosis
Six of ten evaluable myelofibrosis patients who received GB2064 monotherapy for at least six months experienced a ≥ 1-grade reduction in collagen fibrosis...
Galecto Presents Updated Clinical Data at ESMO Congress 2023 and Provides Update on Phase 1b/2a GALLANT-1 Trial
Partial response seen in three of five patients with advanced non-small cell lung cancer who received GB1211 100 mg plus atezolizumab for at least three...
Why Galecto Shares Are Trading Higher By Around 30%; Here Are 20 Stocks Moving Premarket
Gainers
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
Pre-market stock movers are worth keeping track of and we're helping with the biggest winners and losers for Wednesday morning!
Galecto reduces workforce by 70%, explores potential strategic alternatives (NASDAQ:GLTO)
Galecto plans to cut 70% of its workforce and explore strategic alternatives, including mergers and divestitures, as it implements a restructuring plan.
Galecto Announces Plans to Explore Strategic Alternatives
BOSTON, Sept. 26, 2023 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company focused on the development of novel...
Galecto to Present at Investor Conferences in September
BOSTON, Aug. 31, 2023 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company and world leader in galectin biology...